| Methods |
2‐week placebo run‐in; inclusion criteria= DBP 95‐115 mm Hg after run‐in; 8‐week double‐blind treatment |
| Participants |
Trandolapril 2 mg: n=135(55 males,80 females); mean age=53.1(11.3) years; baseline SBP=157.3(15) mm Hg, DBP=101.0(6.3) mm Hg, HR=75.6(9.1) bpm;
Placebo: n=135(55 males,80 females); mean age=53.1(11.3) years; baseline SBP=156.1(18) mm Hg, DBP=100.3(6.6) mm Hg, HR=75.6(9.1) bpm |
| Interventions |
Trandolapril 2 mg once daily;
Placebo |
| Outcomes |
SBP/DBP |
| Notes |
BP change and SD of change not reported, endpoint BP and SD reported; imputed endpoint SD for SD of change; endpoint BP (week 8) data from text, p. 549; BP data for weeks 5 and 8 provided in Figures 1 and 2, p. 550; BP measurement device not reported; time of post‐dose BP measurement not reported; Jadad score=3; funding source= not reported |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Allocation concealment? |
Unclear risk |
B ‐ Unclear |
